Código 901920 (Harmonized System 2012 by 6 digits)
2024: US$799M, Total Trade Exchange
2024: US$530M, International Sales
2024: US$270M, International Purchases
In 2024, the trade exchange (includes international purchases and sales) of Ozone Therapy Devices, Oxygen Therapy and Aerosol Therapy, Respiratory Devices and other Equipment Resuscitation Respiratory Therapy was US$799M.
In 2024, the states with the most international sales in Ozone Therapy Devices, Oxygen Therapy and Aerosol Therapy, Respiratory Devices and other Equipment Resuscitation Respiratory Therapy were Baja California (US$290M), Chihuahua (US$92.6M), Jalisco (US$73.5M), Tamaulipas (US$59.8M), and Sonora (US$13.7M).
The states with the most international purchases in 2024 were Jalisco (US$75.2M), Baja California (US$73.8M), Ciudad de México (US$67.7M), Estado de México (US$22.8M), and Chihuahua (US$11.6M).
In 2024, the main commercial destinations of Ozone Therapy Devices, Oxygen Therapy and Aerosol Therapy, Respiratory Devices and other Equipment Resuscitation Respiratory Therapy were United States (US$452M), France (US$24.2M), New Zealand (US$9.92M), Germany (US$9.66M), and Canada (US$7.66M).
The main commercial origins of Ozone Therapy Devices, Oxygen Therapy and Aerosol Therapy, Respiratory Devices and other Equipment Resuscitation Respiratory Therapy in 2024 were United States (US$141M), China (US$39.9M), Dominican Republic (US$15.2M), New Zealand (US$13.1M), and Germany (US$12.5M).
In the global context, the main exporting countries of Ozone Therapy Devices, Oxygen Therapy and Aerosol Therapy, Respiratory Devices and other Equipment Resuscitation Respiratory Therapy in 2022 were China (US$1.84B), Singapore (US$1.46B), and United States (US$1.36B). In the same year, the main importing countries of Ozone Therapy Devices, Oxygen Therapy and Aerosol Therapy, Respiratory Devices and other Equipment Resuscitation Respiratory Therapy were United States (US$3.43B), Netherlands (US$906M), and Germany (US$716M).
US$799M, Total Trade Exchange (2024)
In 2024, the total trade exchange of Ozone Therapy Devices, Oxygen Therapy and Aerosol Therapy, Respiratory Devices and other Equipment Resuscitation Respiratory Therapy in Mexico (including international purchases and sales) was US$799M.
The visualizations show the net balance of Ozone Therapy Devices, Oxygen Therapy and Aerosol Therapy, Respiratory Devices and other Equipment Resuscitation Respiratory Therapy at the level of states and countries. Colors more similar to blue, indicate that the territory presented a higher level of international sales. Colors more similar to red, indicate that the territory presented a higher level of international purchases.
March, 2025
In March 2025, international sales of Ozone Therapy Devices, Oxygen Therapy and Aerosol Therapy, Respiratory Devices and other Equipment Resuscitation Respiratory Therapy were US$44.9M, while international purchases reached US$17.6M. The above results in a trade balance of US$27.3M.
2025-Q1: US$120M, International Sales
The visualization shows the quarterly concentration of international sales of Ozone Therapy Devices, Oxygen Therapy and Aerosol Therapy, Respiratory Devices and other Equipment Resuscitation Respiratory Therapy at state level.
In the first quarter of 2025, international sales were US$120M, being the states with the most sales Baja California (US$74.7M), Chihuahua (US$22.9M), and Tamaulipas (US$15.6M).
Baja California: US$290M, State with the Most International Sales (2024)
United States: US$452M, Main commercial destination (2024)
In 2024, the states with the highest international sales in Ozone Therapy Devices, Oxygen Therapy and Aerosol Therapy, Respiratory Devices and other Equipment Resuscitation Respiratory Therapy were Baja California (US$290M), Chihuahua (US$92.6M), Jalisco (US$73.5M), Tamaulipas (US$59.8M), and Sonora (US$13.7M).
In 2024, the countries with the most international purchases from Mexico were United States (US$452M), France (US$24.2M), New Zealand (US$9.92M), Germany (US$9.66M), and Canada (US$7.66M).
Jalisco: US$75.2M, State with the Most International Purchases (2024)
United States: US$141M, Main Commercial Origin (2024)
In 2024, the states with the highest international in Ozone Therapy Devices, Oxygen Therapy and Aerosol Therapy, Respiratory Devices and other Equipment Resuscitation Respiratory Therapy were Jalisco (US$75.2M), Baja California (US$73.8M), Ciudad de México (US$67.7M), Estado de México (US$22.8M), and Chihuahua (US$11.6M).
The countries with the most international sales to Mexico in 2024 were United States (US$141M), China (US$39.9M), Dominican Republic (US$15.2M), New Zealand (US$13.1M), and Germany (US$12.5M).
The RCA-Complexity diagram compares the Revelead Comparative Advantages of states in Ozone Therapy Devices, Oxygen Therapy and Aerosol Therapy, Respiratory Devices and other Equipment Resuscitation Respiratory Therapy and the Economic Complexity Index of each state.
RCA values greater than 1 indicate that the state has comparative advantages in Ozone Therapy Devices, Oxygen Therapy and Aerosol Therapy, Respiratory Devices and other Equipment Resuscitation Respiratory Therapy. On the other hand, high levels of complexity (ECI) are associated with higher levels of income, potential for economic growth, lower income inequality and lower emissions.
The visualizations show the global market for Ozone Therapy Devices, Oxygen Therapy and Aerosol Therapy, Respiratory Devices and other Equipment Resuscitation Respiratory Therapy. In both charts, Mexico stands out in order to identify its participation in the export and import market.
In 2022, the main exporting countries of Ozone Therapy Devices, Oxygen Therapy and Aerosol Therapy, Respiratory Devices and other Equipment Resuscitation Respiratory Therapy were China (US$1.84B), Singapore (US$1.46B), and United States (US$1.36B). In the same year, the main importing countries for Ozone Therapy Devices, Oxygen Therapy and Aerosol Therapy, Respiratory Devices and other Equipment Resuscitation Respiratory Therapy were United States (US$3.43B), Netherlands (US$906M), and Germany (US$716M).